维派克斯制药称将寻求非处方医疗器械监管路径预防流感，新冠肺炎

11:36 AM EDT, 07/05/2022 (MT Newswires) -- Virpax Pharmaceuticals said Tuesday it will pursue an over-the-counter medical device regulatory pathway for its AnQlar product.

The intranasal product candidate is being developed as an antiviral barrier against influenza and SARS-CoV-2, the virus that causes COVID-19.

Virpax said it expects the non-prescription medical device pathway to provide a faster drug development timeline and approval track than the OTC non-prescription new drug application pathway originally pursued for AnQlar.